Gossamer Bio Valuation
| GOSS Stock | USD 2.64 0.02 0.75% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Gossamer Bio retains a regular Real Value of $2.39 per share. The prevalent price of the firm is $2.64. Our model calculates the value of Gossamer Bio from evaluating the firm fundamentals such as Shares Outstanding of 231.46 M, return on asset of -0.34, and Return On Equity of -7.83 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Gossamer Bio's valuation include:
Price Book 2.6638 | Enterprise Value | Enterprise Value Ebitda (0.39) | Price Sales 13.8713 | Enterprise Value Revenue 14.3855 |
Overvalued
Today
Please note that Gossamer Bio's price fluctuation is very risky at this time. Calculation of the real value of Gossamer Bio is based on 3 months time horizon. Increasing Gossamer Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Gossamer stock is determined by what a typical buyer is willing to pay for full or partial control of Gossamer Bio. Since Gossamer Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gossamer Stock. However, Gossamer Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.64 | Real 2.39 | Target 9.5 | Hype 2.64 | Naive 3.05 |
The intrinsic value of Gossamer Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gossamer Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gossamer Bio helps investors to forecast how Gossamer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gossamer Bio more accurately as focusing exclusively on Gossamer Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Gossamer Bio's intrinsic value based on its ongoing forecasts of Gossamer Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Gossamer Bio's closest peers.
Gossamer Bio Cash |
|
Gossamer Bio Total Value Analysis
Gossamer Bio is currently projected to have valuation of 633.7 M with market capitalization of 611.04 M, debt of 202.88 M, and cash on hands of 304.38 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gossamer Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
633.7 M | 611.04 M | 202.88 M | 304.38 M |
Gossamer Bio Investor Information
About 79.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.69. Gossamer Bio had not issued any dividends in recent years. Based on the analysis of Gossamer Bio's profitability, liquidity, and operating efficiency, Gossamer Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Gossamer Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Gossamer Bio has an asset utilization ratio of 36.38 percent. This implies that the Company is making $0.36 for each dollar of assets. An increasing asset utilization means that Gossamer Bio is more efficient with each dollar of assets it utilizes for everyday operations.Gossamer Bio Profitability Analysis
Considering Gossamer Bio's profitability and operating efficiency indicators, Gossamer Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in February. Profitability indicators assess Gossamer Bio's ability to earn profits and add value for shareholders.Net Loss | First Reported 2017-03-31 | Previous Quarter -38.3 M | Current Value -48.2 M | Quarterly Volatility 23.9 M |
For Gossamer Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gossamer Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gossamer Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gossamer Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gossamer Bio over time as well as its relative position and ranking within its peers.
Gossamer Bio Earnings per Share Projection vs Actual
The next projected EPS of Gossamer Bio is estimated to be -0.19 with future projections ranging from a low of -0.24 to a high of -0.12. Gossamer Bio's most recent 12-month trailing earnings per share (EPS TTM) is at -0.69. Please be aware that the consensus of earnings estimates for Gossamer Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Gossamer Bio Earnings Estimation Breakdown
The calculation of Gossamer Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Gossamer Bio is estimated to be -0.19 with the future projection ranging from a low of -0.24 to a high of -0.12. Please be aware that this consensus of annual earnings estimates for Gossamer Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.24 Lowest | Expected EPS | -0.12 Highest |
Gossamer Bio Earnings Projection Consensus
Suppose the current estimates of Gossamer Bio's value are higher than the current market price of the Gossamer Bio stock. In this case, investors may conclude that Gossamer Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Gossamer Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 8 | 87.98% | 0.0 | -0.19 | -0.69 |
Gossamer Bio Ownership Allocation
Gossamer Bio has a total of 231.46 Million outstanding shares. The majority of Gossamer Bio outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gossamer Bio to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gossamer Bio. Please pay attention to any change in the institutional holdings of Gossamer Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Gossamer Bio Profitability Analysis
The company reported the previous year's revenue of 114.7 M. Net Loss for the year was (56.53 M) with profit before overhead, payroll, taxes, and interest of 44.05 M.About Gossamer Bio Valuation
The stock valuation mechanism determines Gossamer Bio's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Gossamer Bio based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Gossamer Bio. We calculate exposure to Gossamer Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Gossamer Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 131.9 M | 138.5 M | |
| Pretax Profit Margin | (0.44) | (0.46) | |
| Operating Profit Margin | (0.47) | (0.49) | |
| Net Loss | (0.44) | (0.47) |
Gossamer Bio Current Valuation Indicators
Gossamer Bio's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Gossamer Bio's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Gossamer Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Gossamer Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Gossamer Bio's worth.Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.